Idiopathic Pulmonary Arterial Hypertension (IPAH)

• Mean pulmonary arterial pressure (mPAP) >20 mmHg at rest.
• Pulmonary artery wedge pressure (PAWP) ≤15 mmHg.
• Pulmonary vascular resistance (PVR) >2 Wood units.
  
  

Classification

1. Idiopathic pulmonary arterial hypertension.
2. Heritable pulmonary arterial hypertension.
3. Drug- and toxin-induced pulmonary arterial hypertension.
4. PAH associated with conditions such as connective tissue disease, congenital heart defects, and HIV infection.
5. Persistent pulmonary hypertension of the newborn (PPHN)​
   
   

Genetic Factors

• BMPR2 Mutations:
  • Most common genetic mutation associated with familial IPAH.
  • Found in 11-40% of sporadic cases.
  • Leads to impaired signaling in vascular cells, resulting in proliferative and anti-apoptotic changes.
  • Incomplete penetrance: only 20% of mutation carriers develop the disease.
• Other Genetic Mutations:
  • ACVRL1: Involved in TGF-beta signalling pathways; linked to vascular remodelling.
  • ENG: Encodes endoglin, a protein involved in endothelial homeostasis.
  • SMAD9: Facilitates intracellular TGF-beta signal transduction.
  • CAV1: Encodes caveolin-1, impacting endothelial function.
  • KCNK3: Encodes a potassium channel crucial for regulating pulmonary vascular tone.
    
    

Environmental and Associated Risk Factors

• Drug-Induced Risk:
  • Anorexigens (e.g., appetite suppressants).
  • Alpha-adrenergic stimulants (e.g., cocaine, amphetamines).
• Associated Conditions:
  • Connective tissue diseases.
  • Liver cirrhosis.
  • HIV infection.
• Inflammatory and Environmental Triggers:
  • Chronic inflammation may contribute to endothelial damage.
  • Infections and inflammatory insults suspected but not well-defined.
    
    

Overview

• IPAH is a progressive disease of the pulmonary vasculature with unclear pathogenesis.
• The "multiple-hit theory" suggests that an environmental or hormonal insult in the setting of genetic predisposition triggers endothelial injury, initiating vascular remodeling.
• This process involves:
  • Endothelial dysfunction: Altered production of vasoactive mediators.
  • Vascular remodeling: Intimal and medial proliferation of smooth muscle cells.
  • Thrombosis: In situ thrombus formation in small pulmonary arteries.
    
    

Genetic Contributions

• BMPR2 Mutations:
  • Found in 15-20% of cases previously considered idiopathic.
  • Causes dysregulated TGF-beta signaling, resulting in cell proliferation and resistance to apoptosis.
  • Only 20-25% of mutation carriers develop IPAH, indicating incomplete penetrance and the role of additional factors.
• Other Genetic Mutations:
  • KCNK3: Encodes a potassium channel; mutations lead to impaired ion transport and increased vascular tone.
  • SMAD9, ACVRL1, ENG, and CAV1: Implicated in vascular remodeling and endothelial homeostasis.
  • These mutations highlight the role of genetic predisposition in modifying the pulmonary vasculature.
    
    

Key Vascular Changes

1. Vasoconstriction:
   • Elevated levels of endothelin-1: A potent vasoconstrictor and mitogen.
   • Decreased levels of nitric oxide (NO) and prostacyclin: Impaired vasodilation and antiplatelet activity.
2. Smooth Muscle Cell and Endothelial Proliferation:
   • Intimal and medial thickening driven by pro-inflammatory and mitogenic mediators.
3. Thrombosis:
   • Procoagulant state characterised by elevated fibrinopeptide A, D-dimer, and von Willebrand factor.
     
     

Pathologic Findings

• Histopathology reveals:
  • Medial hypertrophy, intimal hyperplasia, and adventitial fibrosis.
  • Plexiform lesions: Complex vascular remodeling involving obliteration of small pulmonary arteries.
  • Progressive vascular occlusion leads to increased pulmonary vascular resistance (PVR), right ventricular strain, and eventual failure.
    
    

Molecular Mediators

• Endothelin-1:
  • Plasma levels correlate with disease severity.
  • Promotes vasoconstriction, inflammation, and proliferation.
• Nitric Oxide (NO):
  • Levels are reduced due to impaired synthesis or increased consumption.
  • Decreased NO exacerbates vasoconstriction and thrombosis.
• Prostacyclin:
  • Deficiency reduces vasodilation and promotes platelet aggregation.
• Other Factors:
  • Dysregulated serotonin, adrenomedullin, and vascular endothelial growth factor contribute to vascular remodeling.
    
    

Prevalence and Incidence

• Pulmonary arterial hypertension (PAH) is a rare disease with:
  • Prevalence: 48-55 cases per million adults globally.
  • Annual incidence: 2.4-6.0 cases per million people.
• Idiopathic PAH (IPAH) accounts for 30-50% of PAH cases.
• In the United States, IPAH incidence is approximately 2-6 cases per million population annually.
• Variability in prevalence exists worldwide. For instance:
  • The French registry reported a prevalence of 6 cases per million.
  • Registries from the UK and Ireland indicate an increasing prevalence over time, with an observed rise in diagnosis between 2001 and 2009.
    
    

Gender Distribution

• Female predilection is evident in IPAH:
  • Female-to-male ratio varies by region and study:
    • United States: 3.9:1 on average, with clinical trials reporting ratios as high as 4:1.
    • European data indicate ratios from 2.3:1 in younger patients to 1.2:1 in older individuals.
  • The reasons for the higher prevalence among females, particularly women of childbearing age, remain unclear.
    
    

Age at Diagnosis

• Mean age at diagnosis has increased over decades:
  • Early registries (1980s): Mean age was 36 years.
  • More recent registries (e.g., REVEAL and France): Mean age is now approximately 50 years.
  • A significant proportion of cases are diagnosed in individuals over 70 years, particularly in Europe.
    
    

Comorbidities

• Common comorbid conditions in patients with IPAH include:
  • Systemic hypertension.
  • Obesity.
  • Type 2 diabetes mellitus.
  • Ischemic heart disease.
    
    

Mortality

• IPAH contributes to approximately 125-150 deaths per year in the United States, reflecting its progressive and life-threatening nature.
  
  

Key Historical Features

• Symptom Onset and Diagnosis Delay:
  • Average delay from symptom onset to diagnosis: ~2 years.
  • Nonspecific symptoms in early stages often lead to misattribution to age, deconditioning, or other conditions.
• Common Presenting Symptoms:
  • Dyspnea: Most common, affecting ~60% of patients; worsens with exertion.
  • Fatigue and lethargy: Often associated with dyspnea.
  • Syncope or near-syncope: Seen in ~13%, due to inadequate cardiac output or reflex bradycardia during activity.
  • Exertional chest pain: Results from subendocardial hypoperfusion or compression of the left main coronary artery by an enlarged pulmonary artery.
  • Peripheral oedema: Affects ~32%, related to right ventricular (RV) failure and fluid retention.
  • Right upper quadrant pain or abdominal distension: Indicates hepatic congestion or ascites from advanced RV failure.
• Uncommon Symptoms:
  • Cyanosis: Seen in ~20% of cases.
  • Cough, hemoptysis, or hoarseness: Rare, with hoarseness linked to Ortner syndrome (compression of the left recurrent laryngeal nerve by a dilated pulmonary artery).
  • Palpitations: Rare, associated with arrhythmias such as atrial fibrillation or flutter.
    
    

Demographics and Risk Factors

• Age Distribution:
  • Historical US registries (1980s): Mean age at diagnosis was 36 years.
  • Contemporary data:
    • Mean age increased to ~50 years.
    • 9% of patients in the French registry were over 70 years old at diagnosis.
    • European registries report a median diagnosis age of 71 years.
• Gender:
  • Female-to-male ratio varies:
    • Early registries: ~1.7:1.
    • More recent US data: ~3.9:1.
    • In younger patients (<50 years), ratio is ~2.3:1; older patients (~70 years) have a nearly even ratio (~1.2:1).
• Family History:
  • Familial IPAH seen in ~6% of cases.
  • Genetic anticipation and autosomal dominant inheritance with incomplete penetrance.
• Drug Use:
  • History of stimulant use (e.g., methamphetamines) reported in ~28.9%.
  • Appetite suppressants (e.g., aminorex, fenfluramine) are definitive risk factors.
    
    

Historical Findings Related to Disease Progression

• Initial Symptoms:
  • Often exertional and nonspecific, leading to delayed recognition.
  • May include fatigue, dyspnea, and lethargy due to inadequate cardiac output during exercise.
• Symptoms of Right Ventricular Failure:
  • Weight gain from fluid retention.
  • Abdominal swelling or anorexia from hepatic congestion.
  • Progressive dyspnea or signs of systemic venous congestion.
• Advanced Symptoms:
  • Syncope with activity due to fixed cardiac output.
  • Signs of advanced RV failure, including peripheral edema and jugular venous distension.
    
    

Cardiac Auscultation

• Increased intensity of the pulmonic component (P2) of the second heart sound:
  • Common initial finding due to elevated pulmonary pressures.
  • May demonstrate fixed or paradoxical splitting with severe right ventricular (RV) dysfunction.
• Tricuspid regurgitation murmur:
  • High-pitched, holosystolic, best heard at the left sternal border.
• Pulmonic regurgitation murmur (Graham Steell murmur):
  • Early diastolic, high-pitched murmur heard in the pulmonary area.
    
    

Right Ventricular Findings

• RV heave/lift:
  • A left parasternal heave or downward subxiphoid thrust, indicative of RV hypertrophy.
• Right-sided S3 or S4 gallop:
  • Suggests RV failure or reduced compliance.
    
    

Jugular Venous Pressure (JVP)

• Elevated JVP, with:
  • Prominent "a" waves: Poor RV compliance.
  • Prominent "v" waves: Severe tricuspid regurgitation.
  • Hepatojugular reflux may also be present.
    
    

Signs of Right Heart Failure

• Hepatomegaly:
  • Palpable, pulsatile liver due to RV volume overload.
• Peripheral oedema:
  • Pitting oedema, often progressing to ascites in advanced cases.
• Ascites:
  • Indicates decompensated right heart failure.
• Pleural effusion:
  • Often associated with severe decompensation.
    
    

Lung Examination

• Typically normal, as the primary pathology involves the pulmonary vasculature.
  
  

Extremities

• Peripheral oedema:
  • Most often in dependent areas, including sacral oedema in bedridden patients.
• Cyanosis:
  • Present in advanced disease.
    
    

First-Line Investigations

1. Chest X-ray:
   • Findings: Enlarged main pulmonary artery (90%), enlarged hilar vessels (80%), and pruning of peripheral vasculature (51%).
   • Sensitivity: Not specific or sensitive enough to confirm diagnosis. Normal in ~6% of patients.
2. Electrocardiogram (ECG):
   • Findings:
     • Right ventricular hypertrophy (RVH): Tall R wave in V1, qR complex in V1, S1S2S3 pattern.
     • Right axis deviation (QRS axis >100 degrees).
     • Right atrial enlargement (P wave ≥2.5 mm in leads II, III, aVF).
   • Sensitivity/Specificity:
     • Sensitivity: ~73% for right axis deviation and 55% for RVH.
     • Specificity: ~70% for both.
3. Transthoracic Doppler Echocardiography:
   • Purpose: Screening tool; evaluates pulmonary artery systolic pressure (sPAP), tricuspid regurgitation velocity (TRV), and RV function.
   • Findings:
     • TRV >2.8 m/s suggests pulmonary hypertension.
     • Additional measures: RV size, TAPSE <18 mm, RV fractional area change, and RV ejection fraction.
   • Sensitivity: ~79–100%; specificity: ~60–98%.
   • Limitation: Confirmation with right heart catheterisation (RHC) is required.
4. Right Heart Catheterization (RHC):
   • Gold standard diagnostic test for confirming IPAH.
   • Criteria:
     • Mean pulmonary arterial pressure (mPAP) >20 mmHg.
     • Pulmonary arterial wedge pressure (PAWP) ≤15 mmHg.
     • Pulmonary vascular resistance (PVR) >2 Wood units.
       
       

Laboratory Investigations

1. Antinuclear Antibodies (ANA):
   • Purpose: Screens for secondary causes (e.g., connective tissue disease).
   • Result: Negative or low-titer positive (≤1:80).
2. Pulmonary Function Tests (PFTs):
   • Findings:
     • Mild restrictive lung defects (20–50%).
     • Mild diffusion capacity reduction in most patients.
3. Arterial Blood Gas (ABG):
   • Findings:
     • Normal or reduced PaO₂.
     • Reduced PaCO₂, indicating hyperventilation.
4. Brain Natriuretic Peptide (BNP) or N-terminal ProBNP (NT-proBNP):
   • Elevated in right ventricular overload.
   • Threshold:
     • NT-proBNP >300 ng/L or BNP >50 ng/L correlates with severity and mortality risk.
5. HIV Serology:
   • Purpose: Rule out HIV-associated pulmonary hypertension.
6. Liver and Thyroid Function Tests (LFTs/TFTs):
   • Purpose: Exclude liver disease or thyroid dysfunction as secondary causes.
     
     

Specialised and Additional Tests

1. High-Resolution CT (HRCT) and CT Pulmonary Angiography (CTPA):
   • Purpose: Assess interstitial lung disease, emphysema, or chronic thromboembolic disease.
   • Findings:
     • Pulmonary artery dilation, narrowed peripheral vessels, right heart enlargement.
2. Ventilation-Perfusion (V/Q) Scintigraphy:
   • Use: Differentiate chronic thromboembolic pulmonary hypertension from IPAH.
   • Findings: Normal or low probability of thromboembolism.
3. Cardiac MRI:
   • Findings:
     • Assesses RV/LV size and function, myocardial strain, stroke volume.
     • Provides detailed prognosis and monitoring.
4. 6-Minute Walk Test (6MWT):
   • Purpose: Evaluate exercise capacity and disease severity.
   • Parameters: Distance walked, oxygen saturation, and Borg dyspnea scale.
5. Vasodilator Testing:
   • Agents: Inhaled nitric oxide, iloprost, or IV epoprostenol.
   • Purpose: Identify acute responders suitable for calcium channel blocker therapy.
   • Criteria: Fall in mPAP ≥10 mmHg to ≤40 mmHg with unchanged or increased cardiac output.
     
     

Pulmonary Arterial Hypertension (PAH) Associated with Secondary Conditions

1. PAH with Left-sided Heart Disease:
   • Signs/Symptoms:
     • Older age, male preponderance.
     • Typical cardiovascular risk factors (hypertension, diabetes, smoking).
     • Features of left-sided heart failure: gallops, mitral valve murmurs.
   • Investigations:
     • Echocardiography: Left atrial enlargement, systolic/diastolic dysfunction, mitral valve disease.
     • RHC: Elevated pulmonary arterial wedge pressure (PAWP) >15 mmHg.
2. PAH with Respiratory Diseases and Hypoxia:
   • Associated Conditions:
     • Chronic obstructive pulmonary disease (COPD): Smoking history, chronic cough, wheezing.
     • Interstitial lung disease: Inspiratory crackles, clubbing.
     • Sleep-disordered breathing (e.g., obstructive sleep apnea): Snoring, daytime sleepiness.
   • Investigations:
     • PFTs: Obstructive or restrictive pattern.
     • ABG: Hypoxemia, hypercapnia.
     • HRCT: Emphysema, interstitial fibrosis.
3. Chronic Thromboembolic Pulmonary Hypertension (CTEPH):
   • Signs/Symptoms:
     • History of pulmonary embolism.
     • Bruits over lung fields (pulmonary flow murmurs).
   • Investigations:
     • V/Q scan: Segmental or larger unmatched perfusion defects.
     • Pulmonary angiography: Intimal irregularities, abrupt narrowing, vascular webs.
       
       

PAH Associated with Systemic and Connective Tissue Disorders

1. Connective Tissue Disease-Associated PAH:
   • Signs/Symptoms:
     • Multi-system involvement: Arthralgias, skin changes, Raynaud's phenomenon.
     • Scleroderma (especially CREST syndrome) is a significant risk factor.
   • Investigations:
     • ANA, anti-centromere antibodies (scleroderma).
     • Anti-U3 RNP and anticardiolipin antibodies (lupus, mixed connective tissue disease).
2. Congenital Heart Diseases:
   • Simple Shunts:
     • Ventricular septal defect (VSD), atrial septal defect (ASD), or patent ductus arteriosus.
   • Complex Shunts:
     • Eisenmenger syndrome (reversal of shunt flow).
   • Investigations:
     • Contrast echocardiography with agitated saline.
     • RHC for oxygen saturation measurements.
       
       

Miscellaneous Causes of PAH

1. Portopulmonary Hypertension (PAH with Portal Hypertension):
   • Signs/Symptoms:
     • Liver disease (jaundice, ascites, spider telangiectasia).
   • Investigations:
     • Abnormal liver function tests.
     • Doppler ultrasound of the liver.
2. HIV-associated PAH:
   • Signs/Symptoms:
     • Risk factors for HIV infection.
   • Investigations:
     • HIV serology.
3. PAH with Drug and Toxin Exposure:
   • Associated Substances:
     • Appetite suppressants (e.g., aminorex, fenfluramine derivatives).
     • Methamphetamine use.
   • Investigations:
     • Toxicology screening.
4. Pulmonary Veno-occlusive Disease (PVOD):
   • Signs/Symptoms:
     • Severe hypoxemia, ground-glass opacities on imaging.
   • Investigations:
     • HRCT: Ground-glass opacities, septal lines.
     • Bronchoalveolar lavage: Hemosiderin-laden macrophages.
       
       

Common Non-PAH Causes of Dyspnea Mimicking IPAH

1. Chronic Obstructive Pulmonary Disease (COPD):
   • Chronic cough, sputum production, and history of smoking.
2. Heart Failure (HF):
   • Reduced or preserved ejection fraction causing similar symptoms.
3. Anemia:
   • Fatigue and dyspnea due to low oxygen-carrying capacity.
4. Obstructive Sleep Apnea (OSA):
   • Snoring, daytime fatigue, and mild pulmonary hypertension secondary to hypoxia.
     
     

General Goals of Management

• Improve functional status to WHO Functional Class I or II.
• Achieve a 6-minute walk distance (6MWD) of 380–440 meters.
• Normalise right ventricular (RV) function (RV size, pressure, and cardiac index).
• Reduce biomarkers such as B-type natriuretic peptide (BNP).
• Optimise hemodynamics (e.g., right atrial pressure <8 mmHg, cardiac index >2.5 L/min/m²).
  
  

Supportive Therapy

• Exercise Training:
  • Supervised programs recommended for stable patients.
  • Avoid heavy physical exertion or isometric exercises.
• Vaccination:
  • Annual influenza, pneumococcal, and COVID-19 vaccines.
• Psychosocial Support:
  • Advanced care planning and palliative care referrals as needed.
• Diuretics:
  • To manage fluid retention and right ventricular failure.
• Oxygen Therapy:
  • Administered for patients with hypoxemia.
• Iron Supplementation:
  • For iron deficiency, particularly in cases of associated anemia.
• Anticoagulation:
  • Case-by-case use; not routinely recommended.
• Pregnancy Avoidance:
  • IPAH poses significant risks during pregnancy; patients should be counseled on contraception and risks.
    
    

Acute Vasoreactivity Testing

• Used to identify patients with vasoconstriction-dominant disease who may benefit from calcium channel blockers (CCBs).
• Positive Response:
  • Fall in mean pulmonary arterial pressure (mPAP) by ≥10 mmHg to ≤40 mmHg with unchanged/increased cardiac output.
  • Approximately 12% of IPAH patients are responsive.
• Management:
  • Initiate CCBs (e.g., nifedipine, diltiazem, amlodipine) and reassess in 3–6 months.
  • Non-responders or those with unsustained responses transition to other PAH-specific therapies.
    
    

Targeted PAH Therapies

• Epoprostenol (intravenous):
  • Improves exercise capacity, hemodynamics, and survival in severe IPAH.
• Treprostinil (subcutaneous/intravenous):
  • Reduces clinical worsening and improves exercise capacity.
• Iloprost (inhaled):
  • Offers symptom relief with fewer systemic side effects.
    
    

• Bosentan (dual receptor antagonist):
  • Improves functional class, exercise capacity, and hemodynamics.
  • Requires liver function monitoring.
• Ambrisentan (selective receptor antagonist):
  • Associated with fewer hepatic side effects.
• Macitentan:
  • Reduces morbidity and mortality, with long-term efficacy.
    
    

• Sildenafil and Tadalafil:
  • Enhance the nitric oxide (NO) pathway, improving exercise capacity and functional class.
    
    

• Riociguat:
  • Enhances NO-cGMP signaling to reduce pulmonary vascular resistance.
    
    

• Selexipag:
  • Reduces hospitalisations and disease progression.
    
    

• Sotatercept:
  • Targets the bone morphogenetic protein (BMP) pathway to reverse vascular remodeling.
  • Demonstrated efficacy in reducing pulmonary vascular resistance and improving exercise capacity.
    
    

Combination Therapy

• Initial therapy with ERAs and PDE5 inhibitors is preferred for most patients without contraindications.
• Upfront Triple Therapy:
  • For high-risk patients (e.g., ERA + PDE5 inhibitor + intravenous prostanoid).
• Sequential Therapy:
  • For patients who fail monotherapy or dual therapy.
    
    

Advanced Interventions

• Lung Transplantation:
  • Double-lung or heart-lung transplantation is an option for refractory IPAH.
  • Indicated in patients unresponsive to combination therapy and at high risk.
• Balloon Atrial Septostomy:
  • Palliative measure or bridge to transplantation, decompressing the RV and improving systemic perfusion.
    
    

Risk Stratification and Follow-up

• Stratify patients into low, intermediate, and high-risk groups using clinical features, biomarkers, and hemodynamics.
• Goals of therapy:
  • Achieve and maintain a low-risk profile.
  • Monitor patients every 3–6 months with:
    • WHO functional class.
    • 6MWD.
    • Biomarkers (BNP/NT-proBNP).
    • Hemodynamic parameters.
• Adjust therapy based on changes in risk stratification.
  
  

Survival Rates

• Without Treatment: Median survival is 2.8 years, with survival rates of:
  • 1 year: 68%
  • 3 years: 48%
  • 5 years: 34%.
• With Treatment:
  • Epoprostenol Therapy:
    • 1-year: 88%
    • 3-year: 63%
    • 5-year: 47%.
  • Registry data report improvements in survival with modern therapies:
    • 1-year: 91%
    • 3-year: 74%
    • 5-year: 65%.
  • Meta-analyses suggest that targeted PAH therapies reduce all-cause mortality.
    
    

Baseline Prognostic Factors

• Demographics:
  • Male sex.
  • Older age.
• Clinical Features:
  • Syncope.
  • NYHA Functional Class IV.
  • 6-minute walk distance (6MWD) <300–440 meters.
• Echocardiography:
  • Presence of pericardial effusion.
  • Tricuspid annular plane systolic excursion (TAPSE) <1.5 cm.
• Biomarkers:
  • Elevated B-type natriuretic peptide (BNP) >180 ng/L.
• Hemodynamics:
  • Right atrial pressure >15 mmHg.
  • Cardiac index ≤2 L/min/m².
    
    

Prognostic Factors After Therapy

• NYHA Functional Class III or IV after therapy.
• Persistent 6MWD <380 meters.
• Elevated BNP or NT-proBNP.
• Low cardiac index and high right atrial pressure.
  
  

• Achieving NYHA Functional Class I or II.
• Cardiac index ≥2.5 L/min/m².
• Mixed venous oxygen saturation ≥65%.
  
  

• Changes in functional status and biomarkers (e.g., NYHA class, NT-proBNP) are better predictors of survival than changes in 6MWD.
  
  

Impact of Targeted Therapies

• Advances in treatments, including prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, have significantly improved outcomes.
• Long-term studies show improved survival with combination therapies.
  
  

Complications

• Cardiac:
  • Right-sided heart failure.
  • Hepatic congestion.
• Fluid Overload:
  • Pedal oedema.
  • Pleural effusions.
  • Ascites.
• Respiratory:
  • Worsening dyspnea on exertion.
    
    

Key Registry Data

• REVEAL Registry: The largest PAH registry to date identified:
  • 19 independent prognostic factors, allowing for risk stratification and survival prediction.
  • Patients with higher pulmonary capillary wedge pressure (PCWP 16–18 mmHg) had worse survival, often linked to left ventricular diastolic dysfunction.

Cardiovascular Complications

1. Right Ventricular (RV) Failure:
   • Timeframe: Long term.
   • Likelihood: High.
   • Pathophysiology: Progressive pulmonary vascular narrowing increases pulmonary vascular resistance, leading to RV overload, hypertrophy, and eventual failure.
   • Symptoms: Dyspnea, peripheral oedema, ascites, hepatomegaly, and fatigue.
   • Management:
     • Diuretics to manage fluid retention.
     • Digoxin for symptomatic relief.
     • Oxygen supplementation.
     • Pulmonary vasodilator therapy (oral or parenteral).
2. Supraventricular Tachyarrhythmias:
   • Timeframe: Long term.
   • Likelihood: Medium (occurs in 11% of severe cases).
   • Mechanism: Chronic pressure overload leads to structural changes, including enlargement of the right atrium and right ventricle.
   • Common Arrhythmias: Paroxysmal atrial tachycardia.
   • Management:
     • Digoxin to control ventricular rate.
     • Electrical cardioversion for unstable patients.
     • Overdrive pacing and radiofrequency ablation for recurrent episodes.
       
       

Respiratory and Hemodynamic Complications

1. Pleural Effusions:
   • Result from increased venous pressure and systemic congestion.
   • Symptoms include dyspnea and pleuritic chest pain.
   • Management includes thoracentesis and optimising RV function.
2. Dyspnea at Rest:
   • Indicates advanced disease with significant hemodynamic compromise.
   • Treated with oxygen supplementation, diuretics, and vasodilator therapy.
     
     

Abdominal and Systemic Complications

1. Ascites:
   • Mechanism: Hepatic congestion due to elevated venous pressures.
   • Symptoms: Abdominal distension, early satiety, and discomfort.
   • Management: Diuretics and sodium restriction.
2. Death:
   • Primarily due to RV failure or sudden cardiac events in advanced disease.
     
     

Treatment-Related Complications

1. Headache:
   • Timeframe: Variable.
   • Likelihood: High.
   • Causes:
     • Adverse effect of prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.
   • Management: Symptomatic treatment with analgesics or dose adjustments.
2. Central Venous Catheter-Related Infections:
   • Timeframe: Variable.
   • Likelihood: High in patients receiving prostanoids via central venous catheters.
   • Management:
     • Prompt recognition and treatment of bloodstream infections.
     • Preventive strategies include strict aseptic techniques and adherence to catheter care guidelines.
       
       

Rare Complications

1. Paradoxical Embolism:
   • May occur in patients with an undiagnosed atrial septal defect or patent foramen ovale.
   • Can result in stroke or systemic embolism.
2. Hemoptysis:
   • Results from rupture of hypertensive pulmonary arteries.
   • Requires urgent intervention, including embolisation or surgery.
3. Pulmonary Arterial Aneurysm:
   • Rare but associated with a high risk of rupture and mortality.
     
     

1. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: New concepts and experimental therapies. Circulation. 2010;121(18):2045-2066.
2. Benza RL, Miller DP, Barst RJ, et al. Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Chest. 2012;142(2):448-45
3. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension caused by mutations in the bone morphogenetic protein receptor-II gene. American Journal of Human Genetics. 2000;67:737.
4. Farber HW, Loscalzo J. Pulmonary arterial hypertension. New England Journal of Medicine. 2004;351(16):1655-1665
5. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: How REVEAL differs from historic and non-US contemporary registries. Chest. 2011;139(1):128-137.
6. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. European Heart Journal. 2022;43(38):3618-3631.
7. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2016;37(1):67-119.
8. Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis in England: Findings from a multicenter study. Lancet Infectious Diseases. 2010;10(12):835-844.\
9. Hoeper MM, Ghofrani HA, Grünig E, et al. Pulmonary hypertension. Dtsch Arztebl International. 2017;114(5):73-84
10. Humbert M, Lau EMT, Montani D, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2020;142(25):2400-2415.
11. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-163.
12. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: Results from a national registry. American Journal of Respiratory and Critical Care Medicine. 2006;173(9):1023-1030.
13. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Identification of the most accurate estimates from a systematic literature review. Pulmonary Circulation. 2021;11(1):1-12
14. Machado RD, Southgate L, Eichstaedt CA, et al. Pulmonary arterial hypertension: A current perspective on established and emerging molecular genetic defects. Human Mutation. 2015;36(12):1113-1127.
15. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Circulation. 2009;119(16):2250-2294.
16. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal. 2007;30(1):104-109.
17. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801913.
18. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. Journal of the American College of Cardiology. 2002;40(4):780-788.
19. Delcroix M, Vonk Noordegraaf A, Fadel E, et al. Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. European Respiratory Review. 2021;30(162):200213.